About ApicHope Pharmaceutical Company

The company (ApicHope, 300723.sz) was founded in 2002 and listed on the Shenzhen Stock Exchange in 2017. It is an innovative biomedical enterprise focusing on the fields of children's medicine, chronic disease drugs and biogenetic vaccines. The company's business covers the entire pharmaceutical industry chain, and is led by pharmaceutical manufacturing business. It is an innovative biomedical enterprise integrating drug R&D, production and sales. Main products and business: Clindamycin hydrochloride palmitate dispersible tablets, clindamycin hydrochloride palmitate granules, acetylguitamycin dry suspension, oseltamivir phosphate capsules, ambroxol hydrochloride drops, carboxymethane oral solution, levocetirizine hydrochloride oral drops, epinastine hydrochloride granules, montelukast sodium granules, qingxiang clear oral liquid, fuganolin oral liquid, yqi and spleen oral liquid, ginseng cough Solution (compound/granule), acetylglutamine for injection, hepatocyte stimulating hormone for injection, nifedipine control-release tablets, valsartan amlodipine tablets (I), bromhexine hydrochloride Injection, biological vaccine business, etc. Corporate honors: Guangdong Province's contract-abiding and credit-worthy enterprise for ten consecutive years, Guangdong Province's credit benchmark enterprise, Guangdong Province's modern service demonstration enterprise, China's top 100 enterprises with comprehensive chemical research and development capabilities, China's top 100 innovative pharmaceutical enterprises, and China's top 100 pharmaceutical enterprises.